Skip to content

ZenMoney News

How Biotech Investors Can Survive – Or Even Take Advantage Of – This Election Season

While the author of today’s article acknowledges that “biotech investors…tend not to be a squeamish bunch”, he observes that the “looming presidential election could still cause them some visceral discomfort.” Recalling the 2016 presidential campaign, in which both major candidates’ rhetoric regarding drug pricing caused biotech stocks to plummet, he advises that “investors shouldn’t dismiss the possibility of another election-related… 

CLICK HERE »How Biotech Investors Can Survive – Or Even Take Advantage Of – This Election Season

Which Of These Small-Cap Biotechs With Unique COVID-19 Vaccine Candidates Is The Better Buy?

At the beginning of the year, the two biotechs highlighted in today’s article weren’t even big enough to be considered microcap stocks. Now, thanks to their respective COVID-19 vaccine programs, both are fast-growing small-cap stocks with “intriguing twists with their respective COVID-19 vaccine candidates.” So which of these two coronavirus stocks might be the better buy? CLICK HERE.

Presidential Elections And Buying The Biotech Dip

What’s behind biotech’s recent underperformance? One important factor may be the impending presidential election – and as one exchange-traded fund strategist cited in today’s article explains, “…if history repeats, this pullback may represent an attractive buying opportunity.” What does the history of biotech’s performance leading up to and following presidential elections suggest about buying the biotech dip? CLICK HERE.

Emerging Coronavirus Stocks: Potential Multi-Baggers

When it comes to the advantage that emerging coronavirus stocks have over their more established counterparts, the author of today’s article notes that, “While coronavirus vaccine companies such as Moderna, AstraZeneca, and Pfizer have market caps amounting to tens of billions of dollars, small- to mid-cap coronavirus stocks can potentially be multi-baggers, albeit with higher risks.” He proceeds to take… 

CLICK HERE »Emerging Coronavirus Stocks: Potential Multi-Baggers

Do These Heavily Shorted Coronavirus Vaccine Stocks Present Profit Opportunities?

“With all of the hype about the race to develop coronavirus vaccines, it’s not surprising that short-sellers have piled on some of the stocks of biotechs with COVID-19 vaccine candidates,” acknowledges the author of today’s article. He further points out, however, that “if these companies have good news, there could be a short-squeeze scenario where the stocks skyrocket as short-sellers… 

CLICK HERE »Do These Heavily Shorted Coronavirus Vaccine Stocks Present Profit Opportunities?

Cash In On This “Strong Buy” NASH Stock

In the wake of two seemingly negative events, shares of the nonalcoholic steatohepatitis (NASH) drug developer focused on in today’s article experienced a sharp sell-off at the end of last week, but one analyst is imploring investors to “view last week’s weakness as a prime buying opportunity” – and sees massive upside potential of 210%. For more on this stock… 

CLICK HERE »Cash In On This “Strong Buy” NASH Stock

3 Biotech Penny Stocks To Watch Right Now – Including One That’s Been Having An Epic Year

Today’s article highlights three biotech penny stocks to watch right now, including one that the author notes has “had an epic year so far”: It started the year trading under $1 and proceeded to go as high as $5.55 before recently being driven down to as low as $1.68 – and may now be experiencing a turnaround! For more on… 

CLICK HERE »3 Biotech Penny Stocks To Watch Right Now – Including One That’s Been Having An Epic Year

Why These 5 Biotech Stocks Are One Analyst’s Favorites

A hematology drugmaker that could rise at least 60% and a gene therapy developer that could nearly double top the list of the favorite biotech stocks of a newly-hired analyst at Raymond James. Also making the list of top biotech stocks? A neurology stock, a hematology stock – and more. For a closer look at each of these biotech stocks,… 

CLICK HERE »Why These 5 Biotech Stocks Are One Analyst’s Favorites

Biotech Divergence?

When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run.… 

CLICK HERE »Biotech Divergence?

Analysts Are Bullish On These 2 Biotech Stocks

“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.